We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by University of Calgary.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00522496
First Posted: August 29, 2007
Last Update Posted: February 24, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Canadian Intensive Care Foundation
Information provided by:
University of Calgary
  Purpose

The purpose of this study is to:

  1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
  2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
  3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Condition
Brain Injuries, Traumatic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

Resource links provided by NLM:


Further study details as provided by University of Calgary:

Estimated Enrollment: 8
Study Start Date: July 2007
Estimated Study Completion Date: August 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients referred to Foothills Medical Centre, the regional trauma centre for Southern Alberta
Criteria

Inclusion Criteria:

  • Patient is 18 years of age or older
  • Patient has GCS less than 9
  • Patient requires intracranial pressure monitoring
  • Patient life expectancy greater than 72 hours

Exclusion Criteria:

  • Patient's TBI is greater than 24 hours old
  • Patient is less than 18 years of age
  • Patient does not require intracranial pressure monitoring
  • Patient has life expectancy less than 72 hours
  • Patient has GCS greater or equal to 9
  • Patient is currently enrolled in another study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00522496


Contacts
Contact: David A Zygun, MD 403-944-1691 dzygun@ucalgary.ca

Locations
Canada, Alberta
Foothills Medical Centre Recruiting
Calgary, Alberta, Canada, T2N 2T9
Contact: David A Zygun, MD    403-944-1691    dzygun@ucalgary.ca   
Principal Investigator: David A Zygun, MD         
Sub-Investigator: John Hurlbert, MD         
Sub-Investigator: Ian Parney, MD         
Sub-Investigator: Walter Hader, MD         
Sub-Investigator: Clare Gallagher, MD         
Sub-Investigator: Wee Yong, P.hD         
Sub-Investigator: Christopher Doig, MD         
Sub-Investigator: Paul Kubes, MD         
Sub-Investigator: Andreas Kramer, MD         
Sponsors and Collaborators
University of Calgary
Canadian Intensive Care Foundation
Investigators
Principal Investigator: Zygun A David, MD University of Calgary
  More Information

Responsible Party: David Zygun Principal Investigator, University of Calgary
ClinicalTrials.gov Identifier: NCT00522496     History of Changes
Other Study ID Numbers: 20216
First Submitted: August 27, 2007
First Posted: August 29, 2007
Last Update Posted: February 24, 2009
Last Verified: February 2009

Keywords provided by University of Calgary:
Craniocerebral trauma
matrix metalloproteinase
microdialysis

Additional relevant MeSH terms:
Wounds and Injuries
Brain Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System